AstraZeneca plc (NYSE:AZN) Shares Sold by Sei Investments Co.
Sei Investments Co. lessened its holdings in AstraZeneca plc (NYSE:AZN) by 8.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,426,107 shares of the company’s stock after selling 136,346 shares during the quarter. Sei Investments Co. owned approximately 0.05% of AstraZeneca worth $71,059,000 at the end of the most recent quarter.
A number of other institutional investors have also added to or reduced their stakes in AZN. UBS Asset Management Americas Inc. boosted its holdings in AstraZeneca by 9.8% in the second quarter. UBS Asset Management Americas Inc. now owns 4,948 shares of the company’s stock worth $204,000 after purchasing an additional 441 shares during the period. Pacer Advisors Inc. boosted its holdings in AstraZeneca by 58.6% in the third quarter. Pacer Advisors Inc. now owns 14,048 shares of the company’s stock worth $626,000 after purchasing an additional 5,188 shares during the period. Fox Run Management L.L.C. acquired a new position in AstraZeneca in the third quarter worth $253,000. Signaturefd LLC boosted its holdings in AstraZeneca by 14.1% in the third quarter. Signaturefd LLC now owns 14,778 shares of the company’s stock worth $659,000 after purchasing an additional 1,825 shares during the period. Finally, Advisor Partners LLC boosted its holdings in AstraZeneca by 17.1% in the third quarter. Advisor Partners LLC now owns 24,007 shares of the company’s stock worth $1,070,000 after purchasing an additional 3,513 shares during the period. 17.44% of the stock is owned by hedge funds and other institutional investors.
AZN has been the subject of a number of research reports. Svb Leerink initiated coverage on shares of AstraZeneca in a report on Friday, November 22nd. They issued an “outperform” rating for the company. ValuEngine raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Tuesday, February 4th. Leerink Swann began coverage on shares of AstraZeneca in a report on Friday, November 22nd. They issued an “outperform” rating and a $57.00 price objective for the company. Cowen reissued an “outperform” rating and set a $55.00 price target (up previously from $48.00) on shares of AstraZeneca in a report on Monday, December 2nd. Finally, Liberum Capital reissued a “hold” rating on shares of AstraZeneca in a report on Thursday, October 24th. Four investment analysts have rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $50.35.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Further Reading: What is a recession?
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.